Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 297

1.

I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe.

Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, Stefanoff P, Nunes B, Pitigoi D, Larrauri A, Daviaud I, Horvath JK, O'Donnell J, Seyler T, Paradowska-Stankiewicz IA, Pechirra P, Ivanciuc AE, Jiménez-Jorge S, Savulescu C, Ciancio BC, Moren A.

PLoS One. 2011;6(11):e27622. doi: 10.1371/journal.pone.0027622. Epub 2011 Nov 15.

2.

Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.

Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, Rizzo C, Nunes B, Pitigoi D, Larrauri Cámara A, Mosnier A, Horvath JK, O'Donnell J, Bella A, Guiomar R, Lupulescu E, Savulescu C, Ciancio BC, Kramarz P, Moren A.

PLoS Med. 2011 Jan;8(1):e1000388. doi: 10.1371/journal.pmed.1000388. Epub 2011 Jan 11.

3.

Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13.

Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, Rogalska J, Pitigoi D, Paradowska-Stankiewicz I, Reuss A, Jiménez-Jorge S, Daviaud I, Guiomar R, O'Donnell J, Necula G, Głuchowska M, Moren A.

Euro Surveill. 2014 Feb 13;19(6). pii: 20701.

4.

The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).

Valenciano M, Kissling E, Reuss A, Jiménez-Jorge S, Horváth JK, Donnell JM, Pitigoi D, Machado A, Pozo F; I-MOVE Multicentre Case Control Study Team.

Vaccine. 2015 Jun 4;33(24):2813-22. doi: 10.1016/j.vaccine.2015.04.012. Epub 2015 Apr 28.

5.

Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study.

Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, Pitigoi D, Rizzo C, Rebolledo J, Paradowska-Stankiewicz I, Jiménez-Jorge S, Horváth JK, Daviaud I, Guiomar R, Necula G, Bella A, O'Donnell J, Głuchowska M, Ciancio BC, Nicoll A, Moren A.

Euro Surveill. 2013 Jan 31;18(5). pii: 20390.

6.

Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.

Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth JK, Domegan L, Pitigoi D, Machado A, Paradowska-Stankiewicz IA, Bella A, Larrauri A, Ferenczi A; Joan O´Donell, Lazar M, Pechirra P, Korczyńska MR, Pozo F, Moren A; I-MOVE multicentre case-control team.

Euro Surveill. 2016;21(7):pii=30139. doi: 10.2807/1560-7917.ES.2016.21.7.30139. Erratum in: Euro Surveill. 2016;21(8). doi: 10.2807/1560-7917.ES.2016.21.8.30145.

7.

Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study.

Kissling E, Valenciano M; I-MOVE case-control studies team.

Euro Surveill. 2011 Mar 17;16(11). pii: 19818.

8.
9.

Higher vaccine effectiveness in seasons with predominant circulation of seasonal influenza A(H1N1) than in A(H3N2) seasons: test-negative case-control studies using surveillance data, Spain, 2003-2011.

Savulescu C, Jiménez-Jorge S, Delgado-Sanz C, de Mateo S, Pozo F, Casas I, Larrauri A; Spanish Influenza Surveillance System.

Vaccine. 2014 Jul 31;32(35):4404-11. doi: 10.1016/j.vaccine.2014.06.063. Epub 2014 Jun 23.

PMID:
24968153
10.

Estimation of type- and subtype-specific influenza vaccine effectiveness in Victoria, Australia using a test negative case control method, 2007-2008.

Fielding JE, Grant KA, Papadakis G, Kelly HA.

BMC Infect Dis. 2011 Jun 14;11:170. doi: 10.1186/1471-2334-11-170.

11.

Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study.

Jiménez-Jorge S, Savulescu C, Pozo F, de Mateo S, Casas I, Ledesma J, Larrauri A; cycEVA Study Team; Spanish Influenza Sentinel Surveillance System.

Vaccine. 2012 May 21;30(24):3595-602. doi: 10.1016/j.vaccine.2012.03.048. Epub 2012 Mar 31.

PMID:
22472792
12.

Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010.

Savulescu C, Jiménez-Jorge S, de Mateo S, Pozo F, Casas I, Breña PP, Galmés A, Vanrell JM, Rodriguez C, Vega T, Martinez A, Torner N, Ramos JM, Serrano MC, Castilla J, Cenoz MG, Altzibar JM, Arteagoitia JM, Quiñones C, Perucha M, Larrauri A.

BMC Public Health. 2011 Nov 30;11:899. doi: 10.1186/1471-2458-11-899.

13.

Influenza vaccine effectiveness against laboratory confirmed influenza in Greece during the 2013-2014 season: a test-negative study.

Lytras T, Kossyvakis A, Melidou A, Exindari M, Gioula G, Pogka V, Malisiovas N, Mentis A.

Vaccine. 2015 Jan 3;33(2):367-73. doi: 10.1016/j.vaccine.2014.11.005. Epub 2014 Nov 18.

PMID:
25448097
14.

Influenza vaccine effectiveness against medically-attended influenza illness during the 2012-2013 season in Beijing, China.

Yang P, Thompson MG, Ma C, Shi W, Wu S, Zhang D, Wang Q.

Vaccine. 2014 Sep 15;32(41):5285-9. doi: 10.1016/j.vaccine.2014.07.083. Epub 2014 Aug 1.

PMID:
25092635
15.

Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) influenza: estimations from surveillance data in France.

Pelat C, Falchi A, Carrat F, Mosnier A, Bonmarin I, Turbelin C, Vaux S, van der Werf S, Cohen JM, Lina B, Blanchon T, Hanslik T.

PLoS One. 2011 May 10;6(5):e19621. doi: 10.1371/journal.pone.0019621.

16.

Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.

Martínez-Baz I, Navascués A, Pozo F, Chamorro J, Albeniz E, Casado I, Reina G, Cenoz MG, Ezpeleta C, Castilla J; Primary Health Care Sentinel Network and Network for Influenza Surveillance in Hospitals of Navarra.

Hum Vaccin Immunother. 2015;11(7):1626-33. doi: 10.1080/21645515.2015.1038002.

17.

Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination.

Jiménez-Jorge S, de Mateo S, Delgado-Sanz C, Pozo F, Casas I, Garcia-Cenoz M, Castilla J, Pérez E, Gallardo V, Rodriguez C, Vega T, Quiñones C, Martínez E, Vanrell JM, Giménez J, Castrillejo D, Serrano Mdel C, Ramos JM, Larrauri A; Spanish Influenza Sentinel Surveillance System.

BMC Infect Dis. 2013 Sep 22;13:441. doi: 10.1186/1471-2334-13-441.

18.
19.

Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results.

Belongia EA, Kieke BA, Donahue JG, Coleman LA, Irving SA, Meece JK, Vandermause M, Lindstrom S, Gargiullo P, Shay DK.

Vaccine. 2011 Sep 2;29(38):6558-63. doi: 10.1016/j.vaccine.2011.07.002. Epub 2011 Jul 19.

PMID:
21767593
20.

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals.

Rondy M, Launay O, Puig-Barberà J, Gefenaite G, Castilla J, de Gaetano Donati K, Galtier F, Hak E, Guevara M, Costanzo S; European hospital IVE network, Moren A.

Euro Surveill. 2015 Jan 15;20(2). pii: 21011. Erratum in: Euro Surveill. 2015;20(3). pii: 21015. Niesters, Hubert [added].

Supplemental Content

Support Center